Postpartum Haemorrhage Masterclass

Postpartum Haemorrhage: A Clinical Masterclass

An interactive teaching tool built from the 2026 Lancet three-part Series on PPH

Postpartum haemorrhage affects a woman roughly every 1.2 seconds and kills a mother every 12 minutes. Most of these deaths are judged preventable. This module distils the epidemiology, prevention, diagnosis, and treatment of PPH into explorable content, then tests your command of it. Every figure shown traces to one of the three Series papers — none is approximated.

27M
women have a PPH (≥500 mL) each year
Coomarasamy, Lancet 2026
43,000
annual PPH deaths — 1 every 12 min
Coomarasamy, Lancet 2026
52%
of PPH missed by visual estimation
Yunas, Cochrane 2025
60%
reduction in severe outcomes with E-MOTIVE
Gallos, NEJM 2023

Learning objectives

  • Apply the reappraised WHO–FIGO–ICM definition of PPH and its severity tiers.
  • Rank the causes (the four Ts) and the strongest risk factors by effect size.
  • Select evidence-based uterotonic prophylaxis for routine and high-risk births.
  • Deploy the E-MOTIVE / MOTIVE first-response bundle and recognise red flags for life-threatening PPH.
  • Identify the six in-facility delays that cost women their lives.

Publications this tool is built on

Three peer-reviewed Series papers (The Lancet, June 12 2026) plus the underpinning trials and reviews they cite. Full Vancouver citations with annotations are on the Evidence page.

  • Coomarasamy et al. Paper 1 — Epidemiology, consequences, and missed opportunities.
  • Gallos et al. Paper 2 — Prevention: from evidence to implementation at scale.
  • Coomarasamy et al. Paper 3 — Diagnosis and treatment: a race against time.

Learn

Five modules. Tap any to expand. Every number is sourced.

1
Definitions, prevalence & terminology
Paper 1 · the new diagnostic thresholds

Definitions historically varied by both variable (blood loss alone vs. blood loss plus vital signs) and threshold (500 / 750 / 1000 mL). WHO resolved this through an individual-participant-data meta-analysis of 312,151 women across 23 countries, which identified the criteria below as having a prognostic sensitivity of 87–88% and specificity of 67–76% for maternal death or severe morbidity.

Severity & timing tiers

TermDefinition
PPH≥300 mL + any abnormal haemodynamic sign, OR ≥500 mL — whichever first, within 24 h
Severe PPHObjectively measured blood loss ≥1000 mL
Life-threatening PPHShock, collapse, or acute organ failure; usually ≥1500 mL but can occur lower (e.g. severe anaemia)
Refractory PPHNot responded to the first-line treatment bundle
Primary / SecondaryWithin 24 h / after the first 24 h of birth

Prevalence depends entirely on how you measure

SettingObjective (drape)Subjective (visual)
PPH at vaginal birth12.6% (10.1–15.2)3.9% (3.0–4.9)
PPH at caesarean30.9% (24.9–37.6)8.2% (3.7–14.3)
Severe PPH, vaginal3.3% (2.6–4.1)2.3% (1.3–3.6)

Source: Yunas et al, prevalence meta-analysis (81 studies, 42.7M women); Coomarasamy Paper 1.

2
Causes (the four Ts) & risk factors
Paper 1 · 327 studies, 847M women

Pooled rates of the five known causes

CausePooled rate (95% CI)T
Uterine atony70.6% (63.9–77.3)Tone
Genital tract trauma16.9% (9.3–24.6)Trauma
Retained placenta16.4% (12.3–20.5)Tissue
Abnormal placentation3.9% (0.1–7.6)Tissue
Coagulopathy2.7% (0.8–4.5)Thrombin

Rates exceed 100% because causes co-occur. Source: Yunas et al, Lancet 2025.

Risk factors ranked by effect size — sort below

Strong = OR >2 · Moderate = OR 1.5–2 · Weak = OR 1–1.5.

Risk factorCategoryOR (95% CI)

Source: Table 1, Coomarasamy Paper 1 (from Yunas et al and cited sources). Adjusted pooled ORs where available.

3
Prevention & uterotonic prophylaxis
Paper 2 · Cochrane NMA, 122 trials, 121,931 women

No prediction model reliably identifies who will bleed, so uterotonic prophylaxis is advocated for every birth. The network meta-analysis ranked agents by SUCRA (higher = better at preventing PPH ≥500 mL):

Misoprostol + oxytocin
95%
95
Ergometrine + oxytocin
89%
89
Carbetocin
57%
57
Oxytocin
56%
56
Injectable prostaglandin
37%
37
Misoprostol
35%
35
Ergometrine
30%
30
Placebo / none
1

Recommended routine doses

  • Oxytocin 10 IU IM or IV — first line; needs cold chain (2–8 °C).
  • Carbetocin 100 µg IM or IV — heat-stable; preferred where cold chain isn't guaranteed.
  • Misoprostol 400 µg oral — heat-stable alternative; usable by community workers.

Anaemia — the modifiable giant

Affects ~37% of pregnant women globally; OR for PPH 2.36 (1.29–4.32). Defined as Hb <110 g/L (1st/3rd trimester) or <105 g/L (2nd). Treat anaemia: 120 mg elemental iron/day until Hb ≥110 g/L; IV iron if oral fails or correction is urgent.

4
Diagnosis & first-response treatment
Paper 3 · the E-MOTIVE bundle

Mean blood loss at vaginal birth is only 353 mL (median 220 mL) — so 500 mL is already well above average. Subjective visual estimation misses 52% of PPH (sensitivity 48%); a calibrated drape misses only 7% (sensitivity 93%). Neither training nor experience improves the eyeball method.

The MOTIVE first-response bundle (vaginal birth)

A true bundle: every element, every woman, every time the trigger is met — not an algorithm.

M
Massage of uterus
O
Oxytocic drug
T
Tranexamic acid 1 g IV
IV
IV fluids
E
Examine genital tract & escalate
5
Refractory PPH, red flags & the six delays
Paper 3 · a race against time

16.2% (497/3061) of women with PPH progress to refractory PPH despite first-line treatment. Refractory care follows three phases: assess & act → stabilise → operate, with temporising measures (bimanual compression, uterine tamponade, aortic compression, or a non-pneumatic anti-shock garment for transfer).

Red flags for life-threatening PPH

  • Drowsiness, confusion, dyspnoea, oliguria, bruising
  • Blood loss ≥1500 mL · pulse >110 bpm · SBP <90 mmHg · shock index ≥1.7
  • Hb <7 g/dL · fibrinogen <2 g/L · INR ≥1.5 · lactate >2.6 mmol/L

Transfusion targets

ProductTrigger / target
Red cellsSevere PPH (≥1000 mL) or unstable; aim Hb ≥70 g/L
Fibrinogen (cryo/concentrate)Keep Clauss fibrinogen >2 g/L
PlateletsConsider if <75×10⁹/L; aim >50×10⁹/L
Fresh frozen plasmaAfter 4 units RBC, or PT/aPTT >1.5× reference

The six in-facility delays to avoid

  • 1 — Delay in diagnosis (objective measurement + clear trigger)
  • 2 — Delay in first-response treatment (bundle, midwife-authorised)
  • 3 — Delay in escalation (explicit criteria + red flags)
  • 4 — Delay in temporising measures (e.g. NASG)
  • 5 — Delay in identifying the specific cause for targeted treatment
  • 6 — Delay in provision of blood and blood products

Distinct from the older "three delays" model (deciding to seek care · reaching a facility · receiving care).

Interactive

Apply the definition and the bundle — these are deterministic rules from the Series, not predictive models.

WHO–FIGO–ICM definition checker

Enter measured cumulative blood loss and vital signs. The tool applies the 2025 reappraised definition: PPH = ≥300 mL + any abnormal sign, OR ≥500 mL.

Bundle trigger trainer

Which of the three E-MOTIVE trigger criteria fires for this woman? Tap the scenario, then check.

Knowledge check

16 board-style questions. One answer each. Explanations and sources revealed after you answer.

Question 1 of 16
Score 0 / 0

Evidence

Vancouver citations for every data point used above. Primary Series papers first.

PRIMARY SERIES PAPERS — The Lancet, June 12 2026
1
Coomarasamy A, Sindhu KN, Gallos I, et al. Postpartum haemorrhage: epidemiology, consequences, and missed opportunities. Lancet. 2026; published online June 12. doi:10.1016/S0140-6736(26)00902-5.
Epidemiology Source of global numbers, definition, severity tiers, the four Ts, risk-factor table, consequences, and case-fatality disparities.
2
Gallos ID, Sindhu KN, Yunas I, et al. Prevention of postpartum haemorrhage: from evidence to implementation at scale. Lancet. 2026; published online June 12. doi:10.1016/S0140-6736(26)00903-7.
Prevention Source of uterotonic SUCRA rankings, prophylaxis recommendations, anaemia and caesarean targets.
3
Coomarasamy A, Devall AJ, Bell S, et al. Diagnosis and treatment of postpartum haemorrhage: a race against time. Lancet. 2026; published online June 12. doi:10.1016/S0140-6736(26)01031-7.
Treatment Source of MOTIVE bundle, trigger criteria, red flags, transfusion targets, and the six delays.
KEY UNDERPINNING EVIDENCE
4
Gallos I, Devall A, Martin J, et al. Randomized trial of early detection and treatment of postpartum hemorrhage. N Engl J Med. 2023;389:11–21.
RCT The E-MOTIVE trial — 60% reduction in the composite severe outcome (RR 0.40).
5
Yunas I, Gallos ID, Devall AJ, et al. Tests for diagnosis of postpartum haemorrhage at vaginal birth. Cochrane Database Syst Rev. 2025;1:CD016134.
Diagnostic accuracy Visual estimation sensitivity 48% vs. calibrated drape 93%.
6
Gallos ID, Yunas I, Devall AJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2025;4:CD011689.
NMA 122 trials, 121,931 women — the SUCRA prophylaxis rankings.
7
Yunas I, Islam MA, Sindhu KN, et al. Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis. Lancet. 2025;405:1468–80.
Meta-analysis 327 studies — the four Ts pooled rates and risk-factor odds ratios.
8
Gallos I, Williams CR, Price MJ, et al; WHO Consortium on PPH Definition. Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis. Lancet. 2025;406:1969–82.
IPD meta-analysis 312,151 women — basis of the reappraised definition (sensitivity 87–88%).
9
WHO. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. Geneva: World Health Organization; Oct 5 2025.
Guideline The WHO–FIGO–ICM consolidated recommendations operationalised throughout this tool.